ライフサイエンスコーパス: syncytial

1 y 96 h after fertilization, corresponding to syncytial and cellularized stages of endosperm developme

2 orsal accumulates on the ventral side of the syncytial blastoderm.

3 Skeletal muscle myofibers are large syncytial cells comprising hundreds of myonuclei, and in

4 A substantial challenge has been the syncytial cells of the placenta, which have made dissoci

5 ar-1 is required for cells to form following syncytial Drosophila embryo development.

6 tin cytoskeleton to keep mitotic spindles in syncytial embryos from colliding.

7 ) for the induction and maintenance of their syncytial feeding sites in plant roots.

8 e elements were eventually incorporated into syncytial feeding sites.

9 In syncytial filamentous fungi, the acquisition of multicel

10 Multinucleate cellular syncytial formation is a hallmark of skeletal muscle dif

11 Allorecognition mechanisms in syncytial fungi regulate somatic cell fusion by operatin

12 the effects of NPFF-NPFFR2 on expression of syncytial [human chorionic gonadotropin (hCG) beta] and

13 the risk of PE, with particular reference to syncytial knots.

14 d the release of Nodal signals from the yolk syncytial layer (YSL) [9-12].

15 the enveloping cell layer (EVL) and the yolk syncytial layer (YSL) in the gastrulating zebrafish embr

16 expressed mostly in the extraembryonic Yolk Syncytial Layer (YSL) starting before shield stage and d

17 ing attracted to their destination, the yolk syncytial layer, cells appear to migrate away from their

18 essels results in maternal blood bathing the syncytial maternofetal interface.

19 h the dedifferentiation and fragmentation of syncytial muscle cells into mononucleate myoblasts and d

20 These findings reveal that myonuclei within syncytial muscle fibers possess distinct transcriptional

21 the cell cycle and fuse into differentiated syncytial muscle-for which the underlying pathogenetic m

22 of particular interest is the absence of gL syncytial mutants in other herpesviruses.

23 ell fusion, but only for mutants that harbor syncytial mutations in gB (not variants of gK, UL20, or

24 ially true for skeletal muscle, comprised of syncytial myofibers that each accrue hundreds of nuclei

25 ome-like metaphase compartments for dividing syncytial nuclei.

26 nd requires transcriptional reprogramming of syncytial nuclei.

27 he producer may have been a multicellular or syncytial organism able to migrate laterally and vertica

28 roughly for gBsyn variants, which lose their syncytial phenotype in the absence of several accessory

29 re randomly selected to test for respiratory syncytial (RSV), parainfluenza (PIV) and influenza virus

30 extravillous (invasive) cytotrophoblasts and syncytial sprouts vs. villous trophoblasts.

31 indispensable for creating life and building syncytial tissues and organs.

32 velopmental competence, cells that divide in syncytial tissues, and immortal germline cells.

33 und to be important for the activity of some syncytial variants but not others.

34 tants of these were each combined with seven syncytial variants distributed among gK, UL20, and UL24.

35 espiratory syncytial virus", or "respiratory syncytial viral" combined with "mortality", "fatality",

36 aths (n = 32) were attributed to respiratory syncytial virus (21.9%), Pneumocystis jirovecii (18.8%),

37 was similar across all sites for respiratory syncytial virus (4.6 months [4.3 to 4.8]), as it was for

38 a virus (12%), coronavirus (9%), respiratory syncytial virus (6%), and metapneumovirus (6%).

39 mph node transcriptome to Bovine Respiratory Syncytial Virus (BRSV) in a controlled viral challenge.

40 and 2 (BVDV1 and BVDV2), bovine respiratory syncytial virus (BRSV), and bovine herpesvirus (BHV1).

41 manuscript, we show that bovine respiratory syncytial virus (bRSV), which infects cattle, does this

42 us epidemics occurred later than respiratory syncytial virus (by 0.3 months [95% CI -0.3 to 0.9]) whi

43 clude rabies virus (RABV), human respiratory syncytial virus (HRSV), and Ebola virus (EBOV).

44 study the closely related human respiratory syncytial virus (hRSV).

45 ms/eczema during infancy and non-respiratory syncytial virus (mostly rhinovirus) infection; profile B

46 5%), influenza A virus (3%), and respiratory syncytial virus (RSV) (2%).

47 s, influenza B (FluB) virus, and respiratory syncytial virus (RSV) (FFABR assay).

48 either influenza virus (n = 29), respiratory syncytial virus (RSV) (n = 1), influenza virus and RSV (

49 the association of influenza and respiratory syncytial virus (RSV) activity with risk of pulmonary ex

50 Respiratory syncytial virus (RSV) affects most infants early in life

51 vironments and here we show that respiratory syncytial virus (RSV) and herpes simplex virus type 1 (H

52 Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) a

53 Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) c

54 arainfluenza viruses 1-3 (HPIV), respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) f

55 im to characterize the burden of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) L

56 The pathogenesis of respiratory syncytial virus (RSV) and influenza A virus (IAV) have b

57 ow eosinophil-virus interaction, respiratory syncytial virus (RSV) and influenza virus were labeled w

58 Other viral infections, such as respiratory syncytial virus (RSV) and rhinovirus, also seemed to hav

59 in the United States of America: respiratory syncytial virus (RSV) and seasonal influenza.

60 Transplacental respiratory syncytial virus (RSV) antibody transfer has been charact

61 prophylactic antibodies against respiratory syncytial virus (RSV) are in development and likely to b

62 Here we show that RNAs of human respiratory syncytial virus (RSV) are modified by m(6)A within discr

63 s study identified a genotype of respiratory syncytial virus (RSV) associated with increased acute re

64 Rationale: Respiratory syncytial virus (RSV) bronchiolitis causes significant i

65 Infant respiratory syncytial virus (RSV) bronchiolitis in the first 6 month

66 is study evaluates the long-term respiratory syncytial virus (RSV) burden among preterm and full-term

67 Few studies describe the respiratory syncytial virus (RSV) burden in African populations, and

68 and apical release were seen for respiratory syncytial virus (RSV) but not human metapneumovirus (HMP

69 quently tested for influenza and respiratory syncytial virus (RSV) by a polymerase chain reaction tes

70 ue to Legionella, influenza, and respiratory syncytial virus (RSV) by age group.

71 st individuals are infected with respiratory syncytial virus (RSV) by age two, but infection does not

72 afety and immunogenicity of live respiratory syncytial virus (RSV) candidate vaccine, LID/DeltaM2-2/1

73 arainfluenza virus 3 (HPIV3) and respiratory syncytial virus (RSV) cause lower respiratory infection

74 ainst RSV reinfection.IMPORTANCE Respiratory syncytial virus (RSV) causes disease early in life and c

75 Respiratory syncytial virus (RSV) causes exacerbations of asthma and

76 Human respiratory syncytial virus (RSV) causes severe morbidity, which can

77 infection and disease.IMPORTANCE Respiratory syncytial virus (RSV) causes severe respiratory infectio

78 Respiratory syncytial virus (RSV) causes significant morbidity and m

79 Rationale: Respiratory syncytial virus (RSV) causes significant morbidity and m

80 Respiratory syncytial virus (RSV) causes substantial morbidity and m

81 between the age at first severe respiratory syncytial virus (RSV) disease and subsequent asthma.

82 Infants with less severe respiratory syncytial virus (RSV) disease had higher viral loads (VL

83 Despite the severity of respiratory syncytial virus (RSV) disease in older adults, data on i

84 ral load affects the severity of respiratory syncytial virus (RSV) disease in outpatient children.

85 Respiratory syncytial virus (RSV) disease is a major cause of infant

86 at most risk of life threatening respiratory syncytial virus (RSV) disease.

87 her RRs at 1-11 months suggested respiratory syncytial virus (RSV) etiology.

88 The respiratory syncytial virus (RSV) F glycoprotein is a class I fusion

89 th of which cross-react with the respiratory syncytial virus (RSV) F protein.

90 Presatovir is an oral respiratory syncytial virus (RSV) fusion inhibitor targeting RSV F p

91 Inhibitors of the respiratory syncytial virus (RSV) fusion protein block entry of the

92 ecovered 13 (76%) complete human respiratory syncytial virus (RSV) genomes from 17 clinical respirato

93 We aimed to study respiratory syncytial virus (RSV) genotype distribution, clinical pr

94 Data on how respiratory syncytial virus (RSV) genotypes influence disease severi

95 Respiratory syncytial virus (RSV) has eluded active vaccination effo

96 nited States, the seasonality of respiratory syncytial virus (RSV) has traditionally been defined on

97 Despite the prevalence of respiratory syncytial virus (RSV) in adults hospitalized with acute

98 l microbiota to the clearance of respiratory syncytial virus (RSV) in infants hospitalized for bronch

99 spite the high disease burden of respiratory syncytial virus (RSV) in older adults, there is no appro

100 The significant burden of Respiratory Syncytial Virus (RSV) in pediatric and elderly populatio

101 However, both respiratory syncytial virus (RSV) infection and mutations in the rec

102 immune responses at the site of respiratory syncytial virus (RSV) infection are sparse despite nearl

103 Respiratory syncytial virus (RSV) infection causes significant morbi

104 Severe disease following respiratory syncytial virus (RSV) infection has been linked to enhan

105 Early life respiratory syncytial virus (RSV) infection has been linked to the o

106 ith Heligmosomoides polygyrus on respiratory syncytial virus (RSV) infection in a mouse model.

107 explore the association between respiratory syncytial virus (RSV) infection in early life and subseq

108 Respiratory syncytial virus (RSV) infection in lung transplant recip

109 Respiratory syncytial virus (RSV) infection in mouse and human lung

110 f older adults hospitalized with respiratory syncytial virus (RSV) infection in the United States.

111 Respiratory syncytial virus (RSV) infection induces asthma exacerbat

112 Respiratory syncytial virus (RSV) infection is a leading cause of se

113 Severe respiratory syncytial virus (RSV) infection is a major cause of morb

114 Respiratory syncytial virus (RSV) infection is an important cause of

115 Respiratory syncytial virus (RSV) infection is epidemiologically lin

116 Respiratory syncytial virus (RSV) infection is the leading cause of

117 Respiratory syncytial virus (RSV) infection of children previously i

118 Respiratory syncytial virus (RSV) infection of seronegative children

119 Clinical manifestations of respiratory syncytial virus (RSV) infection vary widely from mild, s

120 o the protection of infants from respiratory syncytial virus (RSV) infection, a severe acute lower re

121 l4) was upregulated on APC after respiratory syncytial virus (RSV) infection, and its inhibition lead

122 are in clinical development for respiratory syncytial virus (RSV) infection, including small molecul

123 response in children with acute respiratory syncytial virus (RSV) infection, symptomatic non-RSV res

124 s potentially being important in respiratory syncytial virus (RSV) infection.

125 use of oral ribavirin (RBV) for respiratory syncytial virus (RSV) infections is not well studied.

126 cribed the contribution of adult respiratory syncytial virus (RSV) infections to the use of advanced

127 y viral infections, like IAV and respiratory syncytial virus (RSV) infections, impose great challenge

128 rainfluenza virus 3 (HPIV3), and respiratory syncytial virus (RSV) infections.

129 esponses of AM following IAV and respiratory syncytial virus (RSV) infections.

130 Respiratory syncytial virus (RSV) infects and causes disease in infa

131 Respiratory syncytial virus (RSV) inflicts a significant toll on hum

132 Respiratory syncytial virus (RSV) is a common cause of respiratory t

133 vaccine antigen.IMPORTANCE Human respiratory syncytial virus (RSV) is a global leading cause of infan

134 Respiratory syncytial virus (RSV) is a globally prevalent viral infe

135 Pulmonary infection by the respiratory syncytial virus (RSV) is a large burden on human health,

136 Respiratory syncytial virus (RSV) is a leading cause of hospitalizat

137 Respiratory syncytial virus (RSV) is a leading cause of hospitalizat

138 Respiratory syncytial virus (RSV) is a leading cause of lower respir

139 Respiratory syncytial virus (RSV) is a leading cause of respiratory

140 Respiratory syncytial virus (RSV) is a leading cause of respiratory

141 Respiratory syncytial virus (RSV) is a leading cause of viral pneumo

142 Respiratory syncytial virus (RSV) is a major cause of acute lower re

143 Respiratory syncytial virus (RSV) is a major cause of childhood medi

144 Respiratory syncytial virus (RSV) is a major cause of hospitalizatio

145 Respiratory syncytial virus (RSV) is a major cause of lower respirat

146 Respiratory syncytial virus (RSV) is a major cause of pediatric resp

147 Respiratory syncytial virus (RSV) is a major cause of pneumonia and

148 Respiratory syncytial virus (RSV) is a major cause of severe acute l

149 Human respiratory syncytial virus (RSV) is a major pediatric respiratory p

150 Respiratory syncytial virus (RSV) is a nonsegmented negative-sense (

151 Respiratory syncytial virus (RSV) is a seasonal virus that infects t

152 Respiratory syncytial virus (RSV) is a significant cause of lower re

153 ng antibodies in dams.IMPORTANCE Respiratory syncytial virus (RSV) is a significant human pathogen se

154 Respiratory syncytial virus (RSV) is a top cause of severe lower res

155 Respiratory syncytial virus (RSV) is a worldwide public health conce

156 Respiratory syncytial virus (RSV) is among the most important causes

157 BACKGROUNDRespiratory syncytial virus (RSV) is an important cause of acute pul

158 Respiratory syncytial virus (RSV) is an important cause of respirato

159 Respiratory syncytial virus (RSV) is an important cause of serious r

160 ed negative-strand RNA genome of respiratory syncytial virus (RSV) is encapsidated by the viral nucle

161 Respiratory syncytial virus (RSV) is no exception, as it encodes two

162 The Human respiratory syncytial virus (RSV) is one of the most important viral

163 Respiratory syncytial virus (RSV) is recognised as a leading cause o

164 Although respiratory syncytial virus (RSV) is responsible for more human deat

165 Respiratory syncytial virus (RSV) is the dominant cause of severe lo

166 Respiratory syncytial virus (RSV) is the leading cause of acute resp

167 Respiratory syncytial virus (RSV) is the leading cause of infant low

168 Respiratory syncytial virus (RSV) is the leading cause of lower resp

169 Human respiratory syncytial virus (RSV) is the leading cause of pediatric

170 Respiratory syncytial virus (RSV) is the leading cause of severe res

171 Respiratory syncytial virus (RSV) is the leading global cause of sev

172 Human respiratory syncytial virus (RSV) is the leading viral cause of lowe

173 Respiratory syncytial virus (RSV) is the leading viral cause of seve

174 Respiratory syncytial virus (RSV) is the leading viral pathogen asso

175 Respiratory syncytial virus (RSV) is the most common cause of bronch

176 Respiratory syncytial virus (RSV) is the most common cause of lower

177 Respiratory syncytial virus (RSV) is the most common cause of viral

178 Respiratory syncytial virus (RSV) is the most common viral pathogen

179 Human respiratory syncytial virus (RSV) is the most prevalent worldwide ca

180 Respiratory syncytial virus (RSV) is the primary cause of respirator

181 tiviral drug development against respiratory syncytial virus (RSV) is urgently needed due to the publ

182 E Strain-specific differences in respiratory syncytial virus (RSV) isolates are associated with diffe

183 The association between respiratory syncytial virus (RSV) loads and clinical outcomes in chi

184 Respiratory syncytial virus (RSV) lower respiratory tract infection

185 s with controlled HIV or cleared respiratory syncytial virus (RSV) or influenza virus infections, all

186 transcription and replication by respiratory syncytial virus (RSV) polymerase are helical nucleocapsi

187 Respiratory syncytial virus (RSV) remains a major human pathogen, in

188 ith enhanced rhinovirus (RV) and respiratory syncytial virus (RSV) replication.

189 Respiratory syncytial virus (RSV) represents a threat to infants, th

190 The respiratory syncytial virus (RSV) RNA polymerase, constituted of a 2

191 (wGA) infants aged <12 months at respiratory syncytial virus (RSV) season start.

192 We administered respiratory syncytial virus (RSV) to 58 volunteers, of whom 57% beca

193 g frames (ORFs) in the genome of respiratory syncytial virus (RSV) to codon pair optimization (CPO) b

194 Respiratory syncytial virus (RSV) typically causes winter outbreaks

195 s been made towards an effective respiratory syncytial virus (RSV) vaccine.

196 e have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all epi

197 e, various ORFs in the genome of respiratory syncytial virus (RSV) were codon pair optimized (CPO) by

198 is no effective vaccine against respiratory syncytial virus (RSV), a ubiquitous pathogen of global i

199 evaluate the climate drivers of respiratory syncytial virus (RSV), an important determinant of disea

200 on are being developed for human respiratory syncytial virus (RSV), an important worldwide pediatric

201 ority of bronchiolitis caused by respiratory syncytial virus (RSV), and several RSV vaccines and mono

202 of respiratory viruses including respiratory syncytial virus (RSV), but there are few studies quantif

203 uch as, but not limited to, HIV, respiratory syncytial virus (RSV), herpes simplex virus (HSV), and m

204 s caused by the same serotype of respiratory syncytial virus (RSV), in contrast to infections with mo

205 osed (AFE) for 8 common viruses: respiratory syncytial virus (RSV), influenza virus (Flu), parainflue

206 dae and Pneumoviridae, including respiratory syncytial virus (RSV), mumps virus, and human metapneumo

207 (75.5%) infants with influenza, respiratory syncytial virus (RSV), or human metapneumovirus (hMPV) i

208 nificantly increased the risk of respiratory syncytial virus (RSV)-associated hospitalization in infa

209 Data describing influenza- or respiratory syncytial virus (RSV)-associated hospitalized illness in

210 (or first wheezing episode): (a) respiratory syncytial virus (RSV)-induced bronchiolitis, characteriz

211 f severe disease in infants with respiratory syncytial virus (RSV)-induced lower respiratory tract in

212 Respiratory syncytial virus (RSV)-related acute lower respiratory in

213 ty, and antiviral effects of the respiratory syncytial virus (RSV)-specific fusion inhibitor JNJ-5371

214 ctions caused by viruses such as respiratory syncytial virus (RSV).

215 FDA-approved vaccines for human respiratory syncytial virus (RSV).

216 RNA viral infections, including respiratory syncytial virus (RSV).

217 infections including those from respiratory syncytial virus (RSV).

218 spitalization rates for HMPV and respiratory syncytial virus (RSV).

219 irus (HRV), influenza virus, and respiratory syncytial virus (RSV).

220 virus -0.2 months [-0.6 to 0.1]; respiratory syncytial virus 0.1 months [-0.2 to 0.4]).

221 cted by routine clinical workup (respiratory syncytial virus [n = 3], human metapneumovirus [n = 1],

222 nrolled (77% tested positive for respiratory syncytial virus [RSV]).

223 However, many pathogens (e.g., respiratory syncytial virus [RSV], influenza, dengue, and others) ha

224 virus 4, rhinovirus/enterovirus, respiratory syncytial virus A and B, Bordetella pertussis, Chlamydop

225 Unexpectedly, infection with respiratory syncytial virus alters Rab11A motion in a manner opposit

226 yndrome coronavirus, Zika virus, respiratory syncytial virus and cytomegalovirus replicate in vivo in

227 Previous respiratory syncytial virus and dengue virus vaccine studies reveale

228 ically-relevant Ags derived from respiratory syncytial virus and HIV-1 also exhibited an IgM(LOW) IgD

229 monoclonal antibodies.IMPORTANCE Respiratory syncytial virus and human metapneumovirus are leading ca

230 d mortality settings, similar to respiratory syncytial virus and influenza virus.

231 ) in human infections, including respiratory syncytial virus and influenza, and growing evidence indi

232 h higher levels of antibodies to respiratory syncytial virus and measles virus, compared to uninfecte

233 our step-down level 2 unit, with respiratory syncytial virus and parainfluenza virus being the most c

234 n appears to be within reach for respiratory syncytial virus and promising for influenza virus, where

235 y restricts replication of human respiratory syncytial virus and rhinoviruses.

236 dent pathogen that is related to respiratory syncytial virus and that generates local inflammation as

237 Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).

238 Small molecule inhibits respiratory syncytial virus entry and infection by blocking the inte

239 set month of influenza virus and respiratory syncytial virus epidemics.

240 The prospective Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab (CARESS)

241 The respiratory syncytial virus fusion (F) glycoprotein trimer-stabilize

242 vered that plasma membrane-bound respiratory syncytial virus G rapidly recycles from the membrane via

243 Unlike influenza virus, respiratory syncytial virus had clear seasonal epidemics in both tem

244 ing the human immune response to respiratory syncytial virus has paved the way for new vaccine antige

245 a virus in temperate regions and respiratory syncytial virus in both temperate and tropical regions.

246 The Influenza and Respiratory Syncytial Virus in Infants (IRIS) study was a prospectiv

247 The at-home death rate due to respiratory syncytial virus infection among infants was 0.26 deaths/

248 h has the largest probability of respiratory syncytial virus infection and resembled classic respirat

249 Respiratory syncytial virus is a major cause of acute lower respirat

250 Respiratory syncytial virus is pervasive across multiple severity le

251 tion with parainfluenza virus or respiratory syncytial virus is strongly associated with the developm

252 Respiratory syncytial virus is the leading cause of lower respirator

253 ic months of influenza virus and respiratory syncytial virus on a 5 degrees by 5 degrees grid.

254 l swab testing for influenza and respiratory syncytial virus over 4 days in March 2020.

255 tion of filamentous and branched respiratory syncytial virus particles, and assembly with genomic rib

256 services planning, the timing of respiratory syncytial virus passive prophylaxis, and the strategy of

257 hilus influenzae, influenza, and respiratory syncytial virus respiratory tract infections and ovalbum

258 %) of sCoV cases occurred during respiratory syncytial virus season.

259 Respiratory syncytial virus tests and detections were classified int

260 nthly AAP of influenza virus and respiratory syncytial virus using site-specific temperature and rela

261 gy of influenza virus and future respiratory syncytial virus vaccination.

262 ans given inactivated measles or respiratory syncytial virus vaccines.

263 Respiratory syncytial virus was detected in community, ED (both 0.3

264 Respiratory syncytial virus was detected more frequently in URI visi

265 arainfluenza virus type 3 (28%); respiratory syncytial virus was highly concordant (92%).

266 viral activity against the human respiratory syncytial virus were carried out for selected derivative

267 common human coronaviruses, and respiratory syncytial virus were the most common.

268 015, using the key terms "RSV", "respiratory syncytial virus", or "respiratory syncytial viral" combi

269 moviruses (e.g. Sendai virus and respiratory syncytial virus) by interfering with the virus-induced c

270 r influenza virus, 183 sites for respiratory syncytial virus, 83 sites for parainfluenza virus, and 6

271 hogens (influenza A/H1, A/H3, B, respiratory syncytial virus, and human parainfluenza virus types 1-2

272 In mice infected with respiratory syncytial virus, co-exposure to pollen caused attenuated

273 y of developing vaccines against respiratory syncytial virus, dengue virus, SARS-CoV and Middle East

274 uses, including influenza virus, respiratory syncytial virus, human immunodeficiency virus, human T c

275 ly challenged with either bovine respiratory syncytial virus, infectious bovine rhinotracheitis, bovi

276 human pathogens rabies, measles, respiratory syncytial virus, Nipah, and Ebola, possess an essential

277 nth activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumoviru

278 Influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumoviru

279 an infection of influenza virus, respiratory syncytial virus, parainfluenza virus, or metapneumovirus

280 y viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhi

281 itiatives-group B streptococcus, respiratory syncytial virus, pertussis, and influenza.

282 A study of respiratory syncytial virus-A (RSV A) genotype ON1 genetic variabili

283 Respiratory syncytial virus-associated acute respiratory infection (

284 ted infants have higher risks of respiratory syncytial virus-associated hospitalization than HIV-unex

285 Respiratory syncytial virus-bronchiolitis is a major independent ris

286 Respiratory syncytial virus-confirmed rates were highest among child

287 infection and resembled classic respiratory syncytial virus-induced bronchiolitis; and profile C (36

288 Respiratory syncytial virus-seronegative children ages 6-24 months r

289 h as tuberculosis, influenza and respiratory syncytial virus.

290 utralizing responses against the respiratory syncytial virus.

291 particle bearing an antigen from respiratory syncytial virus.

292 eumovirus, influenza B virus and respiratory syncytial virus.

293 rabies virus, measles virus, and respiratory syncytial virus.

294 80% of the phosphoprotein of the respiratory syncytial virus.

295 ion, and enhances lung injury by respiratory syncytial virus.

296 f sCoVs with influenza virus and respiratory syncytial virus.

297 pic asthma were the first severe respiratory syncytial virus/rhinovirus-negative wheezing episode (ad

298 nd 30.7% influenza/parainfluenza/respiratory syncytial viruses).

299 ry viruses such as influenza and respiratory syncytial viruses.

300 gest for influenza/parainfluenza/respiratory syncytial viruses.